Tens of thousands of patients could benefit from a ‘rapid’ new immunotherapy jab on the NHS for over a dozen different cancers, which can be given in just 60 seconds. The NHS is rolling out a new ...

Syncromune is advancing SYNC-T Therapy SV-102 in the ongoing Phase 2 LEGION-100 study (NCT06533644), which is actively enrolling across multiple sites in the U.S. Please visit www.legion100trial.com ...

FORT MYERS, Fla., Jan. 22, 2026 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) is among the first oncology providers in Florida selected to enroll patients in a phase 3 ...

Targeted therapies are medicines to treat cancer. They work differently than standard chemotherapy. Instead of killing all fast-growing cells or keeping them from dividing, targeted therapies work ...

Investigators from the UCLA Health Jonsson Comprehensive Cancer Center presented new research at the European Society for Medical Oncology (ESMO) Congress, covering advances in immunotherapy, targeted ...

Mayo Clinic Comprehensive Cancer Center scientists, physicians and trainees will present nearly 60 studies on emerging cancer therapies, diagnostics and prevention strategies at the 2026 American ...

Dendritic cells (DCs) have emerged in the field of cancer immunotherapy as the most potent professional antigen-presenting ...